A Clinical Study to Evaluate CAD-1883 in ET

Cadent Therapeutics

Cadence-1 is a clinical trial assessing a novel investigational drug, CAD-1883, as a potential treatment for essential tremor.  This study is designed to evaluate the safety, tolerability and efficacy of CAD-1883 administered twice daily by mouth to adult patients with moderate-to-severe essential tremor.

Enrollment is now open at multiple research centers throughout the US.  Visit ClinicalTrials.gov or cadence-1 to learn more about the study and how to participate.